I am a radiation oncologist who specializes in the treatment of prostate cancer, bladder cancer, and testicular cancer. My particular expertise is managing the early detection and treatment of prostate cancer. Prostate cancers present and progress in different ways. While some prostate cancers pose little threat to health, others may grow aggressively. In many cases, radiotherapy or surgery can be curative. We are actively studying new ways to preserve bowel, urinary and sexual function after radiotherapy and to improve quality of life for patients after treatment. For example, to improve outcomes while minimizing the side effects of radiotherapy, we use sophisticated technologies like proton beam therapy and image-guided, intensity-modulated radiotherapy.
Dr. Bekelman leads research programs in cancer health services and care quality, comparative effectiveness and delivery system and payment reform. His research integrates methods from the fields of epidemiology, clinical trials, health economics and public policy. Dr. Bekelman conducts research to examine the quality, comparative effectiveness, and costs of treatments for prostate, breast, lung and other prevalent cancers using registry, Medicare, and commercial payer administrative claims data and co-leads the multicenter PARTIQoL randomized trial, which compares patient-reported outcomes after proton therapy versus intensity-modulated radiotherapy (IMRT) for prostate cancer. Dr. Bekelman has received research funding from the National Cancer Institute, the American Cancer Society, and philanthropic sources. He did his undergraduate work at Princeton University in the Woodrow Wilson School of Public and International Affairs and his medical training at Yale University, Johns Hopkins, and Memorial Sloan Kettering Cancer Center. Previously, he was a management consultant at the Kalchas Group, advising senior executives of health care and insurance clients on corporate strategy. Dr. Bekelman also served as Special Assistant to the Under Secretary of Defense in the US Department of Defense. He is a board-certified radiation oncologist and practicing physician at the University of Pennsylvania Perelman School of Medicine.
Bekelman JE, Mitra N, Handorf EA, Uzzo RG, Hahn SA, Polsky D, Armstrong K: Effectiveness of Androgen Deprivation Therapy and Radiotherapy for Older Men with Locally Advanced Prostate Cancer. Journal of Clinical Oncology 2014. In press.
Bekelman JE, Sylwestrzak G, Barron J, Liu J, Epstein AJ, Freedman G, Malin J, Emanuel EJ: Uptake and Costs of Hypofractionated vs. Conventional Whole Breast Irradiation After Breast Conserving Surgery in the United States, 2008 - 2013. JAMA 2014. In press.
Kirk ML, Tang S, Zhai H, Vapiwala N, Deville C, James P, Bekelman JE, Christodouleas JP, Tochner Z, and Both S: Comparison of prostate proton treatment planning technique, interfraction robustness, and analysis of single-field treatment feasibility. Practical Radiation Oncology 2014. In press.
Fang P, Mick R, Deville C, Both S, Bekelman J, Christodouleas J, Guzzo T, Tochner Z, Hahn S, Vapiwala N: A Case-Matched Study of Toxicity Outcomes after Proton Therapy and Intensity-Modulated Radiation Therapy for Prostate Cancer. Cancer 2014. In press.
Corcoran AT, Handorf E, Canter D, Tomaszewski JJ, Bekelman JE, Kim SP, Uzzo RG, Kutikov A, Smaldone MC: Variation in performance of candidate surgical quality measures for muscle invasive bladder cancer by hospital type. BJU Int 2014. In press.
Berrington A, Wong J, Kleinerman R, Kim C, Morton L, Bekelman JE: Risk of second cancers according to radiotherapy technique and modality in prostate cancer survivors. Int J Radiat Oncol Biol Phys 2014. In press.
Tomaszewski JJ, Handorf E, Corcoran AT, Wong YN, Mehrazin R, Bekelman JE, Canter D, Kutikov A, Chen DY, Uzzo RG, Smaldone MC: Care transitions between hospitals are associated with treatment delay for patients with muscle invasive bladder cancer. J Urol 192(5): 1349-54, Nov 2014.
Kalbasi A, Swisher-McClure S, Mitra N, Sunderland R, Smaldone M, Uzzo RG, Bekelman JE: Low Rates of Adjuvant Radiation in Non-Metastatic Prostate Cancer Patients with Pathologic Risk Factors. Cancer 120(19): 3089-96, Oct 2014.
Swisher-McClure S, Mitra N, Lin A, Ahn P, Wan F, O'Malley B, Weinstein GS, Bekelman JE: Risk of Fatal Cerebrovascular Accidents after External Beam Radiation Therapy for Early Stage Glottic Larynx Cancer. Head and Neck 36(5): 611-616, May 2014.
Goldsmith B, Baumann BC, He J, Tucker K, Bekelman J, Deville C, Vapiwala N, Vaughn D, Keefe SM, Guzzo T, Malkowicz BS, Christodouleas JP: Occult pelvic lymph node involvement in bladder cancer: implications for definitive radiation. Int J Radiat Oncol Biol Phys 88(3): 603-10, Mar 2014.
back to top
Last updated: 12/09/2014
The Trustees of the University of Pennsylvania